FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040390735> ?p ?o ?g. }

• W2040390735 endingPage "2441" @default.
• W2040390735 startingPage "2437" @default.
• W2040390735 abstract "BACKGROUND Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL. METHODS Between June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T-cell lymphoma, unspecified (PTCLU) with exclusive skin involvement (n = 5 patients); and Sezary syndrome (SS) (n = 1 patient) were enrolled in a 7-institution, Phase II trial and treated with gemcitabine. This drug was given on Days 1, 8, and 15 of a 28-day schedule at a dose of 1200 mg/m2 intravenously over 30 minutes for a total of 6 cycles. RESULTS Of the 32 patients studied, 7 (22%) achieved a complete response (CR) and 17 (53%) achieved a partial response (PR), whereas the remaining 8 patients showed no benefit from the treatment. Five of the CRs were confirmed histologically. The CR and PR rates were found to be the same for patients with MF and PTCLU, respectively. The median duration of CR was 10 months (range, 4–22 mos). Treatment appeared to be well tolerated; hematologic toxicity was mild and no nausea/emesis or organ toxicity was noted. CONCLUSIONS The results of the current Phase II study demonstrate the activity of gemcitabine as a single agent in untreated CTCL patients. Further studies using gemcitabine in combination, either contemporary or sequentially, with other drugs in patients with advanced stage, untreated CTCL are needed. Cancer 2005. © 2005 American Cancer Society." @default.
• W2040390735 created "2016-06-24" @default.
• W2040390735 creator A5005238069 @default.
• W2040390735 creator A5010943353 @default.
• W2040390735 creator A5017472528 @default.
• W2040390735 creator A5036579401 @default.
• W2040390735 creator A5039006383 @default.
• W2040390735 creator A5039739851 @default.
• W2040390735 creator A5043985252 @default.
• W2040390735 creator A5044224344 @default.
• W2040390735 creator A5046025763 @default.
• W2040390735 creator A5054730003 @default.
• W2040390735 creator A5058320427 @default.
• W2040390735 creator A5063734987 @default.
• W2040390735 creator A5087333640 @default.
• W2040390735 date "2005-01-01" @default.
• W2040390735 modified "2023-10-17" @default.
• W2040390735 title "Gemcitabine as frontline treatment for cutaneous T-cell lymphoma" @default.
• W2040390735 cites W1749229087 @default.
• W2040390735 cites W1822166136 @default.
• W2040390735 cites W1912693401 @default.
• W2040390735 cites W1914654455 @default.
• W2040390735 cites W1959866484 @default.
• W2040390735 cites W1976342263 @default.
• W2040390735 cites W1986778063 @default.
• W2040390735 cites W1989716470 @default.
• W2040390735 cites W1991858554 @default.
• W2040390735 cites W1998484959 @default.
• W2040390735 cites W2002547761 @default.
• W2040390735 cites W2008453753 @default.
• W2040390735 cites W2013082284 @default.
• W2040390735 cites W2013686729 @default.
• W2040390735 cites W2029854218 @default.
• W2040390735 cites W2032419702 @default.
• W2040390735 cites W2056101225 @default.
• W2040390735 cites W2107202569 @default.
• W2040390735 cites W2124482385 @default.
• W2040390735 cites W2135087888 @default.
• W2040390735 cites W2143662019 @default.
• W2040390735 cites W2261126455 @default.
• W2040390735 cites W4293241248 @default.
• W2040390735 cites W91395500 @default.
• W2040390735 doi "https://doi.org/10.1002/cncr.21449" @default.
• W2040390735 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16216001" @default.
• W2040390735 hasPublicationYear "2005" @default.
• W2040390735 type Work @default.
• W2040390735 sameAs 2040390735 @default.
• W2040390735 citedByCount "144" @default.
• W2040390735 countsByYear W20403907352012 @default.
• W2040390735 countsByYear W20403907352013 @default.
• W2040390735 countsByYear W20403907352014 @default.
• W2040390735 countsByYear W20403907352015 @default.
• W2040390735 countsByYear W20403907352016 @default.
• W2040390735 countsByYear W20403907352017 @default.
• W2040390735 countsByYear W20403907352018 @default.
• W2040390735 countsByYear W20403907352019 @default.
• W2040390735 countsByYear W20403907352020 @default.
• W2040390735 countsByYear W20403907352021 @default.
• W2040390735 countsByYear W20403907352022 @default.
• W2040390735 countsByYear W20403907352023 @default.
• W2040390735 crossrefType "journal-article" @default.
• W2040390735 hasAuthorship W2040390735A5005238069 @default.
• W2040390735 hasAuthorship W2040390735A5010943353 @default.
• W2040390735 hasAuthorship W2040390735A5017472528 @default.
• W2040390735 hasAuthorship W2040390735A5036579401 @default.
• W2040390735 hasAuthorship W2040390735A5039006383 @default.
• W2040390735 hasAuthorship W2040390735A5039739851 @default.
• W2040390735 hasAuthorship W2040390735A5043985252 @default.
• W2040390735 hasAuthorship W2040390735A5044224344 @default.
• W2040390735 hasAuthorship W2040390735A5046025763 @default.
• W2040390735 hasAuthorship W2040390735A5054730003 @default.
• W2040390735 hasAuthorship W2040390735A5058320427 @default.
• W2040390735 hasAuthorship W2040390735A5063734987 @default.
• W2040390735 hasAuthorship W2040390735A5087333640 @default.
• W2040390735 hasBestOaLocation W20403907351 @default.
• W2040390735 hasConcept C121608353 @default.
• W2040390735 hasConcept C126322002 @default.
• W2040390735 hasConcept C141071460 @default.
• W2040390735 hasConcept C203014093 @default.
• W2040390735 hasConcept C2776090121 @default.
• W2040390735 hasConcept C2776780870 @default.
• W2040390735 hasConcept C2777589544 @default.
• W2040390735 hasConcept C2777756187 @default.
• W2040390735 hasConcept C2777891184 @default.
• W2040390735 hasConcept C2779338263 @default.
• W2040390735 hasConcept C2780258809 @default.
• W2040390735 hasConcept C2780580376 @default.
• W2040390735 hasConcept C29730261 @default.
• W2040390735 hasConcept C31760486 @default.
• W2040390735 hasConcept C71924100 @default.
• W2040390735 hasConcept C8891405 @default.
• W2040390735 hasConcept C90924648 @default.
• W2040390735 hasConceptScore W2040390735C121608353 @default.
• W2040390735 hasConceptScore W2040390735C126322002 @default.
• W2040390735 hasConceptScore W2040390735C141071460 @default.
• W2040390735 hasConceptScore W2040390735C203014093 @default.
• W2040390735 hasConceptScore W2040390735C2776090121 @default.
• W2040390735 hasConceptScore W2040390735C2776780870 @default.

• next